. 2021 Apr 16;13(8):1931. doi: 10.3390/cancers13081931

Table 1.

International Society of Cutaneous Lymphomas (ISCL)/European Organization for Research and Treatment of Cancer (EORTC) revision to the staging of mycosis fungoides (MF) and Sézary syndrome (SS). T: skin, N: lymph node, M: viscera, B: blood, OS: overall survival, DSS: disease-free survival. N/S: not specified. ^a Data extracted from [18].

Stage		T	N	M	B	Median OS (Years)	5 Year OS ^a (%)	5 Year DSS (%)
Early	IA	1	0	0	0–1
	IA	Limited patches or plaques <10% skin surface	No nodal involvement	No visceral involvement	<1000 atypical cells	35.5	N/S	98
	IB	2	0	0	0–1
	IB	Patches or plaques ≥10% skin surface	No nodal involvement	No visceral involvement	<1000 atypical cells	21.5	86	89
	IIA	1–2	1–2	0	0–1
	IIA	Any patches or plaques	Aggregates of atypical cells	No visceral involvement	<1000 atypical cells	15.8	N/S	89
Advanced	IIB	3	0–2	0	0–1
	IIB	Tumoral lesions	No involvement or aggregates of atypical cells	No visceral involvement	<1000 atypical cells	4.7	62	56
	III	4	0–2	0	0–1
	III	Erythroderma	No involvement or aggregates of atypical cells	No visceral involvement	<1000 atypical cells	4.7	N/S	56
	IIIA	4	0–2	0	0
	IIIA	Erythroderma	No involvement or aggregates of atypical cells	No visceral involvement	<250 atypical cells	4.7	60	54
	IIIB	4	0–2	0	1
	IIIB	Erythroderma	No involvement or aggregates of atypical cells	No visceral involvement	250–1000 atypical cells	3.4	54	48
	IVA₁	1–4	0–2	0	2
	IVA₁	Any skin involvement	No involvement or aggregates of atypical cells	No visceral involvement	>1000 atypical cells + clonality	3.8	52	41
	IVA₂	1–4	3	0	0–2
	IVA₂	Any skin involvement	Partial or complete effacement of nodal architecture	No visceral involvement	<1000 or >1000 atypical cells + clonality	2.1	34	23
	IVB	1–4	0–3	1	0–2
	IVB	Any skin involvement	Any nodal involvement	Visceral involvement	<1000 or >1000 atypical cells + clonality	1.4	23	18